Physician profile
Cari Page
NPI 1467423947
$1,609.88
in general payments reported to CMS, 2019-2025
16 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $101 · 2021: $77.52 · 2022: $121 · 2023: $320 · 2024: $273 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $683.07 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $317.92 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $220.59 | 2019-2020 | |
| Abbvie INC. | $78.52 | 2021-2024 | |
| Pfizer INC. | $69.04 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.58 | 2019 | |
| Abbott Laboratories | $33.89 | 2019 | |
| Medtronic Minimed, INC. | $30.09 | 2020 | |
| Supernus Pharmaceuticals, INC. | $26.78 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.91 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.26 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.01 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $14.01 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.45 | 2019 | |
| Merck Sharp & Dohme LLC | $11.69 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cari Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.